- NetraMark Holdings (CSE: AIAI, OTCQB: AINMF) announces a shareholder conference call on April 15, 2025.
- The company highlights its strategic partnership with Worldwide Clinical Trials to enhance clinical trials in neuroscience and oncology.
- NetraAI technology offers explainable AI to identify subpopulations in clinical trials, reducing overfitting and improving success rates.
NetraMark Holdings Inc. (CSE: AIAI, OTCQB: AINMF), an AI company specializing in clinical trial analytics, has scheduled a shareholder conference call for Tuesday, April 15, 2025, from 4:00 to 4:30 pm EST. CEO George Achilleos will lead the session, focusing on strategic developments and the company's growth trajectory.
A key highlight of the conference call will be NetraMark's strategic partnership with Worldwide Clinical Trials. This collaboration integrates NetraAI into a range of clinical trials, particularly in the fields of neuroscience and oncology, aimed at accelerating the adoption of NetraMark’s cutting-edge technology.
The call will also delve into NetraMark's regulatory strategy, showcasing how its explainable AI capabilities enhance clinical trials and FDA submissions. NetraAI stands out by offering explainable insights, utilizing novel algorithms to identify patient subpopulations in small datasets and reduce overfitting, which is a common challenge in clinical data analysis.
Additionally, NetraMark has fortified its marketing and public relations efforts by extending its agreement with 1502656 B.C. Ltd. for six months, providing additional compensation of $200,000 CDN for public relations services. This move aims to boost the company’s public and investor awareness, supporting its upcoming ventures and technological innovations.
For investors interested in joining the call, access is available via a video link at this link or by dialing (CA) 1-605-313-5544 with access code 8003978#.
